Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 993 matching trials from the live ClinicalTrials.gov search.

Filters: Palo Alto, California Clear all

Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma
Interventions: Laboratory Biomarker Analysis, Taselisib; Other · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1106
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 688 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions: Azacitidine, Cytarabine, Decitabine, Laboratory Biomarker Analysis, Midostaurin, Nivolumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 506
States / cities: Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 337 more

Conditions: Head and Neck Cancer
Interventions: carboplatin, paclitaxel; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 17
States / cities: Palo Alto, California • Stanford, California • Tampa, Florida + 13 more

Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Intensity-Modulated Radiation Therapy, Peposertib; Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 27
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more

Conditions: Alzheimer's Disease, Dementia
Interventions: Risperidone, Gabapentin; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Mild to Moderate Traumatic Brain Injury, Cognitive Rehabilitation, Veteran
Interventions: GOALS TH, EDU TH; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Ibrutinib, Obinutuzumab, Observation Activity, Venetoclax; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 65 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 857
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 555 more

Conditions: Aging
Interventions: exercise; Other
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS), Lymphoma, Non-Hodgkin, Acute Lymphoblastic Leukemia (ALL), Myeloproliferative Syndrome, Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia
Interventions: CD34+ Hematopoietic Progenitor Cells (HSPC), Regulatory T-Cells (Treg), Conventional T-Cells (Tcon), Myeloablative Conditioning Regimen; Biological · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 13 Years to 73 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 604
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 426 more

Conditions: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions: Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration; Biological · Drug · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 429
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: PLN-74809, Placebo; Drug
Lead sponsor: Pliant Therapeutics, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 79
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more

Conditions: Solid Tumors Harboring MET Amplification
Interventions: Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 18
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 14 more

Conditions: Dual Diagnosis
Interventions: Intensive referral to dual-focused self-help; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Carboplatin, Pemetrexed, Selpercatinib; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 265
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Anaheim, California + 219 more

Conditions: Alcohol Dependence, Drug Dependence
Interventions: Telephone Case Monitoring, Continuing Care as Usual; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 3
States / cities: Palo Alto, California • Topeka, Kansas • St Louis, Missouri

Conditions: Alzheimer Disease
Interventions: AR1001, Placebo; Drug
Lead sponsor: AriBio Co., Ltd.; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 1,535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 75
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 62 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Insomnia, Spinal Cord Injury, Tetraplegia, Sleep Disorders
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Smoking, Bipolar Disorder
Interventions: Experimental plus Nicotine Replacement Therapy, Control plus Nicotine Replacement Therapy; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Palo Alto, California • Denver, Colorado • Bedford, Massachusetts + 1 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions: Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine; Drug · Procedure · Biological + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 2,175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2038
U.S. locations: 999
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more

Conditions: Posttraumatic Stress Disorder
Interventions: Clinician-Supported PTSD Coach, Primary Care Mental Health Integrated Care as Usual; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Palo Alto, California • Syracuse, New York

Conditions: Diabetic Kidney Disease
Interventions: Pentoxifylline, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 2,376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 31 more

Conditions: Aortoiliac Aneurysms, Iliac Aneurysms
Interventions: Zenith® Branch Endovascular Graft-Iliac Bifurcation,; Device
Lead sponsor: Cook Research Incorporated; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 26
States / cities: Phoenix, Arizona • Palo Alto, California • Stanford, California + 20 more

Search by objective public record fields.

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Specific Interventions for Agitation in Alzheimer's Disease

Goal-oriented Telehealth Rehabilitation of Executive Functioning for Veterans With Chronic TBI

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Role of Exercise in Reversal of Hospitalization-associated Disability in Elderly

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Dual Diagnosis Self-Help Referral

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

LINK: Aftercare Monitoring Project

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia

Web-Delivered Acceptance & Commitment Therapy for Smokers With Bipolar Disorder

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

An RCT of a Primary Care-Based PTSD Intervention: Clinician-Supported PTSD Coach

Pentoxifylline in Diabetic Kidney Disease

PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation